255 related articles for article (PubMed ID: 32087593)
1. Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?
Prezioso C; Zingaropoli MA; Iannetta M; Rodio DM; Altieri M; Conte A; Vullo V; Ciardi MR; Palamara AT; Pietropaolo V
Mult Scler Relat Disord; 2020 Jun; 41():102008. PubMed ID: 32087593
[TBL] [Abstract][Full Text] [Related]
2. Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment.
Prezioso C; Grimaldi A; Landi D; Nicoletti CG; Brazzini G; Piacentini F; Passerini S; Limongi D; Ciotti M; Palamara AT; Marfia GA; Pietropaolo V
Viruses; 2021 Aug; 13(9):. PubMed ID: 34578264
[TBL] [Abstract][Full Text] [Related]
3. Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment.
Pietropaolo V; Bellizzi A; Anzivino E; Iannetta M; Zingaropoli MA; Rodio DM; Morreale M; Pontecorvo S; Francia A; Vullo V; Palamara AT; Ciardi MR
J Neurovirol; 2015 Dec; 21(6):653-65. PubMed ID: 25930159
[TBL] [Abstract][Full Text] [Related]
4. Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study.
Bellizzi A; Anzivino E; Rodio DM; Cioccolo S; Scrivo R; Morreale M; Pontecorvo S; Ferrari F; Di Nardo G; Nencioni L; Carluccio S; Valesini G; Francia A; Cucchiara S; Palamara AT; Pietropaolo V
Virol J; 2013 Sep; 10():298. PubMed ID: 24079660
[TBL] [Abstract][Full Text] [Related]
5. Absence of JC polyomavirus in stool samples of patients with multiple sclerosis despite high anti-JCV antibodies in serum.
Schweitzer F; Ladwig A; Opala S; Laurent S; Schroeter M; Goelz S; Fink GR; Wieland U; Silling S; Warnke C
Mult Scler Relat Disord; 2024 Jul; 87():105664. PubMed ID: 38735204
[TBL] [Abstract][Full Text] [Related]
6. JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.
Basnyat P; Virtanen E; Elovaara I; Hagman S; Auvinen E
J Neurovirol; 2017 Oct; 23(5):734-741. PubMed ID: 28831768
[TBL] [Abstract][Full Text] [Related]
7. Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients.
Reid CE; Li H; Sur G; Carmillo P; Bushnell S; Tizard R; McAuliffe M; Tonkin C; Simon K; Goelz S; Cinque P; Gorelik L; Carulli JP
J Infect Dis; 2011 Jul; 204(2):237-44. PubMed ID: 21673034
[TBL] [Abstract][Full Text] [Related]
8. JCPyV miR-J1-5p in Urine of Natalizumab-Treated Multiple Sclerosis Patients.
Agostini S; Mancuso R; Costa AS; Caputo D; Clerici M
Viruses; 2021 Mar; 13(3):. PubMed ID: 33809082
[TBL] [Abstract][Full Text] [Related]
9. Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab.
Diotti RA; Capra R; Moiola L; Caputo V; De Rossi N; Sangalli F; Martinelli V; Burioni R; Clementi M; Mancini N
Viruses; 2016 May; 8(5):. PubMed ID: 27164128
[TBL] [Abstract][Full Text] [Related]
10. JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus.
Zingaropoli MA; Iannetta M; Pontecorvo S; Anzivino E; Prezioso C; Rodio DM; Morreale M; D'Abramo A; Oliva A; Lichtner M; Cortese A; Frontoni M; Pietropaolo V; Francia A; Mastroianni CM; Vullo V; Ciardi MR
Biomed Res Int; 2018; 2018():5297980. PubMed ID: 29682547
[TBL] [Abstract][Full Text] [Related]
11. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
Domínguez-Mozo MI; García-Montojo M; Arias-Leal A; García-Martínez Á; Santiago JL; Casanova I; Galán V; Arroyo R; Fernández-Arquero M; Alvarez-Lafuente R
Eur J Neurol; 2016 Jan; 23(1):182-9. PubMed ID: 26498276
[TBL] [Abstract][Full Text] [Related]
12. Comparison of qPCR with ddPCR for the Quantification of JC Polyomavirus in CSF from Patients with Progressive Multifocal Leukoencephalopathy.
Ngouth N; Monaco MC; Walker L; Corey S; Ikpeama I; Fahle G; Cortese I; Das S; Jacobson S
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746716
[TBL] [Abstract][Full Text] [Related]
13. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
Chen Y; Bord E; Tompkins T; Miller J; Tan CS; Kinkel RP; Stein MC; Viscidi RP; Ngo LH; Koralnik IJ
N Engl J Med; 2009 Sep; 361(11):1067-74. PubMed ID: 19741227
[TBL] [Abstract][Full Text] [Related]
14. JCPyV NCCR analysis in PML patients with different risk factors: exploring common rearrangements as essential changes for neuropathogenesis.
Ciardi MR; Zingaropoli MA; Iannetta M; Prezioso C; Perri V; Pasculli P; Lichtner M; d'Ettorre G; Altieri M; Conte A; Pietropaolo V; Mastroianni CM; Vullo V
Virol J; 2020 Feb; 17(1):23. PubMed ID: 32046748
[TBL] [Abstract][Full Text] [Related]
15. Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.
Skarlis C; Papadopoulos V; Raftopoulou S; Mavragani CP; Evangelopoulos ME
J Neurol Sci; 2024 Jun; 461():123046. PubMed ID: 38761670
[TBL] [Abstract][Full Text] [Related]
16. John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis.
Kapica-Topczewska K; Collin F; Tarasiuk J; Czarnowska A; Chorąży M; Mirończuk A; Kochanowicz J; Kułakowska A
Eur Neurol; 2020; 83(5):487-492. PubMed ID: 33027785
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
[TBL] [Abstract][Full Text] [Related]
18. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
19. Increased frequency of JC-polyomavirus detection in rheumatoid arthritis patients treated with multiple biologics.
Verheyen J; Maizus K; Feist E; Tolman Z; Knops E; Saech J; Spengler L; Waterboer T; Burmester GR; Pawlita M; Pfister H; Rubbert-Roth A
Med Microbiol Immunol; 2015 Oct; 204(5):613-8. PubMed ID: 25678083
[TBL] [Abstract][Full Text] [Related]
20. Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.
Jelcic I; Combaluzier B; Jelcic I; Faigle W; Senn L; Reinhart BJ; Ströh L; Nitsch RM; Stehle T; Sospedra M; Grimm J; Martin R
Sci Transl Med; 2015 Sep; 7(306):306ra150. PubMed ID: 26400911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
